Titlebook: Valproate; Wolfgang L?scher Book 1999 Springer Basel AG 1999 bipolar disorder.chemistry.clinical trial.development.drug.drugs.epilepsy.med

Jargon

The discovery of valproatey was serendipitously discovered by Pierre Eymard in France in 1962. Valproic acid (VPA; valproate; di-.-propylacetic acid, DPA; 2-propylpentanoic acid, or 2-propylvaleric acid) was first synthesized in 1882, by Burton [1], but there was no known clinical use until its anticonvulsant activity was fo

fatty-streak

Horizon

紡織品

Absorption, distribution, and excretionor heterocyclic anticonvulsants. The pharmacokinetics of valproate have been the subject of regular reviews over the two decades of valproate’s usage as an anticonvulsant [1–4]. This chapter provides a summary of the salient features of the pharmacokinetics of valproate, and additionally, perspectiv

平靜生活

Toxicitylar disorders [2] or as an adjunct therapeutic for alcohol addiction during withdrawal periods [3]. Other indications for this drug are under investigation like the treatment of intractable hiccups [4] and as an anti-emetic in chemotherapy [5]. The side-effects caused by this important drug will the

友好

Treatment of epilepsies in adults]. Clinical trials by Carraz et al. [3] followed the initial animal studies that showed efficacy against seizures caused by both pentylenetetrazol and maximal electroshock. Valproic acid was used to treat seizures in Europe almost 15 years before approval in the USA [4]. This drug was used initially

痛苦一下

Valproate use in psychiatry: A focus on bipolar illness affective illness. Early studies in France by Lambert and in Germany by Emrich presaged the widespread use of the drug in the 1990s [1, 2]. However, it was not until the publication of a series of double-blind controlled studies comparing valproate with lithium and placebo in the early 1990s that i

Fsh238

厭惡

Adverse effects and interactions with other drugs1960s when few clinical trials were required, and those performed have simply used incidence reporting following passive inquiry. The prevalence and incidence of adverse effects has not been reported at different points during these early trials and, apart from withdrawal from the trial, no quantifi

aggrieve

The future of valproatessed elsewhere in this volume, but the future of VPA is unknown because it depends on whether safer and more effective medications become available for these conditions. Nevertheless, in this chapter we speculate on the future of VPA based on the current knowledge of its properties and use.